GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TRACON Pharmaceuticals Inc (NAS:TCON) » Definitions » Operating Margin %

TRACON Pharmaceuticals (TRACON Pharmaceuticals) Operating Margin % : 91.36% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is TRACON Pharmaceuticals Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. TRACON Pharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $2.78 Mil. TRACON Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $3.05 Mil. Therefore, TRACON Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2023 was 91.36%.

The historical rank and industry rank for TRACON Pharmaceuticals's Operating Margin % or its related term are showing as below:

TCON' s Operating Margin % Range Over the Past 10 Years
Min: -8192.77   Med: -296.9   Max: -57.27
Current: -73.87


TCON's Operating Margin % is ranked better than
59.63% of 1028 companies
in the Biotechnology industry
Industry Median: -171.86 vs TCON: -73.87

TRACON Pharmaceuticals's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

TRACON Pharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $2.78 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.90 Mil.


TRACON Pharmaceuticals Operating Margin % Historical Data

The historical data trend for TRACON Pharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TRACON Pharmaceuticals Operating Margin % Chart

TRACON Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -8,192.77 - -57.27

TRACON Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -8.66 - 91.36

Competitive Comparison of TRACON Pharmaceuticals's Operating Margin %

For the Biotechnology subindustry, TRACON Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TRACON Pharmaceuticals's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TRACON Pharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where TRACON Pharmaceuticals's Operating Margin % falls into.



TRACON Pharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

TRACON Pharmaceuticals's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-6.898 / 12.045
=-57.27 %

TRACON Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=2.782 / 3.045
=91.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TRACON Pharmaceuticals  (NAS:TCON) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


TRACON Pharmaceuticals Operating Margin % Related Terms

Thank you for viewing the detailed overview of TRACON Pharmaceuticals's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


TRACON Pharmaceuticals (TRACON Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
4350 La Jolla Village Drive, Suite 800, San Diego, CA, USA, 92122
TRACON Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its cost efficient, contract research organization (CRO) independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the United States. The company's drug candidate includes Envafolimab, TRC102, TRC253, and Bispecific Antibodies.
Executives
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Charles Theuer director, officer: President and CEO C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
Bonne J. Adams officer: Chief Operating Officer C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
Scott B. Brown officer: Chief Accounting Officer (PAO) C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
William R Larue director C/O TRACON PHARMACEUTICALS, INC., 8910 UNIVERSITY CENTER LANE, SUITE 700, SAN DIEGO CA 92122
Carol C. Lam director C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, STE 800, SAN DIEGO CA 92122
Saundra L Pelletier director C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Lisa Johnson-pratt director C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
Ikarian Healthcare Master Fund, L.p. 10 percent owner, other: Member of 10% Group 100 CRESCENT COURT, SUITE 1620, DALLAS TX 75201
Mark C Wiggins officer: Chief Business Officer 12671 HIGH BLUFF DRIVE SUITE 200, SAN DIEGO CA 92130
Neil Shahrestani 10 percent owner, other: Member of 10% Group 12806 WINDING CREEK DRIVE, FRISCO TX 75035
Ikarian Healthcare Fund Gp, L.p. 10 percent owner, other: Member of 10% Group 100 CRESCENT COURT, SUITE1620, DALLAS TX 75201
Chart Westcott Living Trust 10 percent owner, other: Member of 10% Group 100 CRESCENT COURT, SUITE1620, DALLAS TX 75201
Ikarian Capital, Llc 10 percent owner, other: Member of 10% Group 100 CRESCENT COURT, SUITE 1620, DALLAS TX 75201
Puissance Cross-border Opportunities V Llc 10 percent owner 950 THIRD AVENUE, 25TH FL, NEW YORK NY 10022

TRACON Pharmaceuticals (TRACON Pharmaceuticals) Headlines

From GuruFocus

Is TRACON Pharmaceuticals Inc Undervalued Following the Latest Insider Buy?

By GuruFocus Research GuruFocus Editor 07-25-2022